CPT1B抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09565(CPT1B Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P09565(CPT1B Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The CPT1B antibody is a crucial tool for studying carnitine palmitoyltransferase 1B (CPT1B), a mitochondrial enzyme central to fatty acid metabolism. CPT1B, one of three CPT1 isoforms (CPT1A, CPT1B, CPT1C), is predominantly expressed in skeletal muscle and heart tissues. It catalyzes the rate-limiting step of fatty acid β-oxidation by transferring long-chain fatty acids into mitochondria, a process vital for energy production during fasting or prolonged exercise. Dysregulation of CPT1B is linked to metabolic disorders, including obesity, insulin resistance, and cardiovascular diseases, making it a target for metabolic research.

CPT1B antibodies are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression, localization, and tissue-specific distribution. They help investigate CPT1B’s role in metabolic adaptations, such as exercise-induced changes or dietary interventions. Researchers also employ these antibodies to explore pathological conditions, such as cancer (where altered lipid metabolism supports tumor growth) or muscle-related metabolic syndromes. Specificity validation (e.g., knockout controls) is critical due to structural similarities among CPT1 isoforms. Commercial CPT1B antibodies are typically raised against unique epitopes in the N-terminal or C-terminal regions, with host species varying (rabbit, mouse). Their applications extend to preclinical studies targeting CPT1B for therapeutic modulation in metabolic diseases.